86 results on '"Afif, W."'
Search Results
2. A278 ACCEPTABILITY, FEASIBILITY, AND IMPACT OF THE MYGUT DIGITAL HEALTH PLATFORM IN THE MONITORING AND MANAGEMENT OF INFLAMMATORY BOWEL DISEASE
3. A252 DRUG DISCONTINUATION AND PERSISTENT SYMPTOMS AMONG THE USERS OF BIOSIMILAR AND LEGACY ANTI-TNF DRUGS IN A REAL-WORLD CANADIAN IBD COHORT
4. P306 Rectal bleeding and stool frequency are strong predictors of endoscopic and histologic activity in ulcerative colitis patients, a prospective cohort study
5. P356 Long-term outcome of UC patients in clinical remission with different level of mucosal activity: real world, retrospective, multicontinental study
6. P412 Faecal Calprotectin as a predictor of endoscopic and histologic remission in patients with Ulcerative Colitis
7. P716 Efficacy and safety of upadacitinib during induction in Crohn’s disease: Real-world experience
8. P672 Occurrence of malignancy among infliximab biosimilar and bio-originator initiators in Canada: a comparative population-based analysis
9. A191 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
10. A34 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
11. P793 Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis
12. P417 Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Study
13. A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
14. A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
15. A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW
16. P321 Mucosal Healing and Clinical remission after Treatment with Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA study): final results from a prospective, open-label, single-arm study
17. P318 Safety of Biological Therapies in Elderly IBD: a Systematic Review and Meta-analysis
18. P524 Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn’s disease
19. P247 Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts
20. DOP25 Clinical outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
21. P582 Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s disease
22. P451 Evaluating drug sustainability, efficacy and safety of biologic agents in elderly patients with Inflammatory Bowel Disease: a single center retrospective study
23. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort
24. POS1420 RISK OF SERIOUS INFECTIONS IN OFFSPRING EXPOSED IN UTERO TO USTEKINUMAB OR VEDOLIZUMAB
25. P643 Patient perspectives and expectations in inflammatory bowel disease: a systematic review
26. P119 There is minimal agreement on the recognition of deep ulcers as seen on endoscopy in patients with Inflammatory Bowel Disease: a national survey
27. P364 Patient reported outcomes, partial MAYO score and SCCAI are equally accurate in predicting mucosal healing in UC: final results form a prospective study
28. DOP86 Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extension
29. DOP26 The relationship between vedolizumab therapeutic drug monitoring, biomarkers of inflammation, and clinical outcomes in Inflammatory Bowel Disease in the real-world setting
30. DOP18 UCEIS is associated with PRO2, partial Mayo and SCCAI remission in UC: Final results from a prospective study
31. P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension
32. DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
33. P552 Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort
34. A192 A MEDICAL SUMMARY TEMPLATE FOR THE TRANSFER OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TRANSITIONING FROM PEDIATRIC TO ADULT CARE
35. A174 PATIENT PERSPECTIVES AND EXPECTATIONS IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW
36. A157 REAL-WORLD TIGHT OBJECTIVE MONITORING WITH ADALIMUMAB LEADS TO EARLIER DOSE OPTIMIZATION AND HIGHER CLINICAL REMISSION RATES AT 12 MONTHS.
37. A232 EFFICACY OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS: REAL-WORLD DATA
38. P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial
39. DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study
40. Undiagnosed depression, persistent depressive symptoms and seeking mental health care: analysis of immigrant and non-immigrant participants of the Canadian Longitudinal Study of Aging
41. P841 Evaluation of gut microbiota composition in NAFLD with UC pancolitis in clinical remission: a pilot study
42. P512 Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data
43. P807 UCEIS is associated with PRO2, partial Mayo and SCCAI remission in UC: preliminary results from a prospective study
44. P773 Patient reported outcomes, partial MAYO score and SCCAI are equally accurate in predicting mucosal healing in UC: Preliminary results from a prospective study
45. DOP45 Increased prevalence but not incidence of myocardial infarction and stroke in patients with inflammatory bowel diseases in Quebec in 1996–2015
46. P570 The burden of anaemia remains significant over time in patients with inflammatory bowel disease at a tertiary referral centre
47. A134 HIGH ADHERENCE TO SURVEILLANCE GUIDELINES IN IBD RESULTS IN LOW CRC AND DYSPLASIA RATES, WHILE RATES OF DYSPLASIA AND CANCER ARE LOW BEFORE THE SUGGESTED START OF SURVEILLANCE. RESULTS FROM A TERTIARY IBD CENTER.
48. A105 HIGH ADHERENCE TO SURVEILLANCE GUIDELINES IN IBD RESULTS IN LOW CRC AND DYSPLASIA RATES, WHILE RATES OF DYSPLASIA AND CANCER ARE LOW BEFORE THE SUGGESTED START OF SURVEILLANCE. RESULTS FROM A TERTIARY IBD CENTER.
49. A78 IMPACT OF IMPLEMENTING A RAPID ACCESS CLINIC IN A HIGH-VOLUME INFLAMMATORY BOWEL DISEASE CENTER: ACCESSIBILITY, REASOURCE UTILISATION AND OUTCOMES
50. A76 HIGH ADHERENCE TO SURVEILLANCE GUIDELINES IN IBD RESULTS IN LOW CRC AND DYSPLASIA RATES, WHILE RATES OF DYSPLASIA AND CANCER ARE LOW BEFORE THE SUGGESTED START OF SURVEILLANCE. RESULTS FROM A TERTIARY IBD CENTER.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.